DaVita Dirección

Dirección controles de criterios 3/4

El CEO de DaVita's es Javier Rodriguez , nombrado en Jun 2019, tiene una permanencia de 4.83 años. compensación anual total es $2.98M, compuesta por 40.2% salario y 59.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.8% de las acciones de la empresa, por valor de $93.29M. La antigüedad media del equipo directivo y de la junta directiva es de 5.7 años y 4.8 años, respectivamente.

Información clave

Javier Rodriguez

Chief Executive Officer (CEO)

US$6.7m

Compensación total

Porcentaje del salario del CEO	21.0%
Permanencia del CEO	4.9yrs
Participación del CEO	0.8%
Permanencia media de la dirección	4.9yrs
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

DaVita Stock Is A Hold As It Expands In Latin America

Mar 18

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

Mar 13

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Mar 04

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16

DaVita could benefit from legislation that would return dialysis protection to Medicare

Aug 16

We Think DaVita (NYSE:DVA) Is Taking Some Risk With Its Debt

Aug 14

DaVita stock dips as peer Fresenius outlook weighed down by labor cost, inflation

Jul 28

DaVita: Valuation Turning Attractive

Jul 16

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Jul 13

Here's Why I Think DaVita (NYSE:DVA) Is An Interesting Stock

May 15

DaVita Offers Stability During Market Volatility

May 12

Here's Why DaVita (NYSE:DVA) Has A Meaningful Debt Burden

Apr 29

Is It Time To Consider Buying DaVita Inc. (NYSE:DVA)?

Apr 14

DaVita's Wide Moat Is Undervalued

Feb 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Javier Rodriguez en comparación con los beneficios de DaVita?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$816m
Dec 31 2023	US$7m	US$1m	US$692m
Sep 30 2023	n/a	n/a	US$596m
Jun 30 2023	n/a	n/a	US$454m
Mar 31 2023	n/a	n/a	US$500m
Dec 31 2022	US$3m	US$1m	US$547m
Sep 30 2022	n/a	n/a	US$680m
Jun 30 2022	n/a	n/a	US$834m
Mar 31 2022	n/a	n/a	US$903m
Dec 31 2021	US$3m	US$1m	US$978m
Sep 30 2021	n/a	n/a	US$984m
Jun 30 2021	n/a	n/a	US$883m
Mar 31 2021	n/a	n/a	US$791m
Dec 31 2020	US$73m	US$1m	US$783m
Sep 30 2020	n/a	n/a	US$832m
Jun 30 2020	n/a	n/a	US$824m
Mar 31 2020	n/a	n/a	US$816m
Dec 31 2019	US$17m	US$1m	US$705m
Sep 30 2019	n/a	n/a	US$623m
Jun 30 2019	n/a	n/a	US$548m
Mar 31 2019	n/a	n/a	US$551m
Dec 31 2018	US$8m	US$900k	US$616m
Sep 30 2018	n/a	n/a	US$617m
Jun 30 2018	n/a	n/a	US$698m
Mar 31 2018	n/a	n/a	US$652m
Dec 31 2017	US$8m	US$900k	US$909m

Compensación vs. Mercado: La compensación total de Javier($USD2.98M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Javier ha aumentado más de un 20% en el último año.

CEO

Javier Rodriguez (52 yo)

4.9yrs

Permanencia

US$6,712,328

Compensación

Mr. Javier J. Rodriguez serves as an Independent Director at Gilead Sciences, Inc. since June 15, 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rod...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Javier Rodriguez	CEO & Executive Director	4.9yrs	US$6.71m	0.80% $ 96.3m
Joel Ackerman	CFO & Treasurer	7.3yrs	US$6.87m	0.16% $ 19.3m
Kathleen Waters	Chief Legal & Public Affairs Officer	8yrs	US$5.61m	0.068% $ 8.1m
James Hearty	Chief Compliance Officer	6.2yrs	US$2.73m	0.014% $ 1.6m
Michael Staffieri	Chief Operating Officer of Kidney Care	10.2yrs	US$10.42m	0.23% $ 27.6m
Christopher Berry	Group VP & Chief Accounting Officer	less than a year	sin datos	sin datos
Misha Palecek	Chief Transformation Officer of U.S. Kidney Care Business	no data	sin datos	sin datos
Jeffrey Giullian	Chief Medical Officer of Kidney Care	4.3yrs	sin datos	sin datos
Partha Das	Chief Medical Officer of DaVita International	5.8yrs	sin datos	sin datos
Mandy Hale	Chief Nursing Officer	3.9yrs	sin datos	sin datos
Tina Livaudais	Chief Nursing Officer of Kidney Care	2.7yrs	sin datos	sin datos
Mihran Naljayan	Chief Medical Officer of Home Modalities & Pediatrics	2.3yrs	sin datos	sin datos

4.9yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de DVA se considera experimentado (4.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Javier Rodriguez	CEO & Executive Director	4.9yrs	US$6.71m	0.80% $ 96.3m
John Nehra	Independent Director	23.5yrs	US$344.96k	0.089% $ 10.7m
Charles Berg	Director	17.2yrs	US$322.46k	0.029% $ 3.5m
Barbara Desoer	Independent Director	8.6yrs	US$384.96k	0.018% $ 2.2m
Phyllis Yale	Independent Director	7.8yrs	US$374.96k	0.017% $ 2.1m
Wendy Schoppert	Independent Director	less than a year	US$106.86k	0.00093% $ 111.6k
Pamela Arway	Independent Chair	15yrs	US$497.46k	0.027% $ 3.3m
Dennis Pullin	Independent Director	less than a year	sin datos	sin datos
Adam Schechter	Independent Director	1.7yrs	US$334.96k	0.0030% $ 358.9k
Jason Hollar	Independent Director	2yrs	US$364.96k	0.0040% $ 483.7k
Gregory Moore	Independent Director	2.7yrs	US$355.89k	0.0054% $ 649.4k

4.9yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de DVA se considera experimentada (4.8 años de antigüedad promedio).

DaVita Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

High number of new directors

DaVita Inc., Annual General Meeting, Jun 06, 2024

Davita Announces Dennis Pullin to Its Board of Directors

Chief Operating Officer of Kidney Care exercised options and sold US$3.0m worth of stock

CEO & Executive Director exercised options and sold US$36m worth of stock

Chief Compliance Officer recently sold US$3.0m worth of stock

Recent updates

Price target increased by 9.0% to US$140

High number of new directors

DaVita Inc., Annual General Meeting, Jun 06, 2024

DaVita Inc. to Report Q1, 2024 Results on May 02, 2024

Davita Announces Dennis Pullin to Its Board of Directors

DaVita Stock Is A Hold As It Expands In Latin America

Chief Operating Officer of Kidney Care exercised options and sold US$3.0m worth of stock

Market Might Still Lack Some Conviction On DaVita Inc. (NYSE:DVA) Even After 27% Share Price Boost

CEO & Executive Director exercised options and sold US$36m worth of stock

Price target increased by 7.4% to US$131

Is There Now An Opportunity In DaVita Inc. (NYSE:DVA)?

Chief Compliance Officer recently sold US$3.0m worth of stock

Chief Compliance Officer notifies of intention to sell stock

DaVita Inc. (NYSE:DVA) Analysts Are Pretty Bullish On The Stock After Recent Results

Price target increased by 14% to US$120

Is DaVita (NYSE:DVA) Using Too Much Debt?

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

DaVita: Assessing After The Rally

DaVita Inc.'s (NYSE:DVA) Subdued P/E Might Signal An Opportunity

CEO & Executive Director exercised options and sold US$16m worth of stock

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 13%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Has A Somewhat Strained Balance Sheet

DaVita: Simple And Compelling After Sell-Off

Returns On Capital Signal Difficult Times Ahead For DaVita (NYSE:DVA)

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

Investor sentiment deteriorates as stock falls 19%

DaVita: Continued Economic Hurdles, Market Expectations May Be Correct

Chief Legal & Public Affairs Officer notifies of intention to sell stock

Is It Too Late To Consider Buying DaVita Inc. (NYSE:DVA)?

Price target increased by 7.3% to US$113

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

DaVita (NYSE:DVA) Takes On Some Risk With Its Use Of Debt

DaVita Inc. Announces Management Changes

DaVita: Breakout Not Supported Without Leverage Effects, Reiterate Hold

Returns At DaVita (NYSE:DVA) Appear To Be Weighed Down

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

DaVita Inc. (NYSE:DVA) Shares Could Be 41% Below Their Intrinsic Value Estimate

Chief Legal & Public Affairs Officer recently sold US$1.0m worth of stock

CEO & Executive Director notifies of intention to sell stock

Price target increased by 8.1% to US$96.27

Price target increased by 8.3% to US$94.38

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

What Is DaVita Inc.'s (NYSE:DVA) Share Price Doing?

Price target increased by 8.6% to US$88.80

These 4 Measures Indicate That DaVita (NYSE:DVA) Is Using Debt Extensively

Investors Met With Slowing Returns on Capital At DaVita (NYSE:DVA)

Director recently sold US$108k worth of stock

Are Investors Undervaluing DaVita Inc. (NYSE:DVA) By 40%?

Director exercised options and sold US$106k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 7.0% to US$86.50

DaVita HealthCare Partners Q4 2022 Earnings Preview

Moon Capital - DaVita: A Recession-Resistant Cash Generating Machine

DaVita Inc. to Report Q4, 2022 Results on Feb 22, 2023

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

Is DaVita (NYSE:DVA) A Risky Investment?

DaVita: Shares Still Appear Cheap After Outlook Cut, Technicals Suggest Caution

Consensus EPS estimates fall by 21%

Independent Director recently bought US$356k worth of stock

Price target decreased to US$83.57

Third quarter 2022 earnings: EPS misses analyst expectations

DaVita Q3 2022 Earnings Preview

Is Now The Time To Look At Buying DaVita Inc. (NYSE:DVA)?

DaVita Inc. to Report Q3, 2022 Results on Oct 28, 2022

DaVita: Solid Valuation And Cash Flow, Price Recovering After SCOTUS Ruling

DaVita Inc. Appoints Adam H. Schechter to Board of Directors